Introduction
Epstein-Barr virus (EBV), a human herpesvirus, is strongly associated with two human malignancies, Burkitt's lymphoma and nasopharyngeal carcinoma. EBV has also been implicated in the B cell lymphomas and lymphoproliferative disorders that occur in immunosuppressed recipients of organ allografts (1) (2) (3) , and in AIDS patients with disease-associated immunosuppression (4, 5) . While the EBV genome is generally present in the proliferating cells in these conditions, there is limited information on its role in pathogenesis, since the natural host range is limited to man. Although new world monkeys, particularly cotton-top tamarins, develop tumors and lymphoproliferative disease 14-21 d after EBV injection (6) (7) (8) , these animals are endangered and not generally available. In this paper we describe a novel model for EBV-induced human lymphoproliferative disease. We report that EBV infection of mice with severe combined immunodeficiency (SCID)' (9) reconstituted by intraperitoneal injection of PBL from EBV seronegative donors (or tonsil cells) is followed 19- Histopathology. Tissue samples were fixed in B-5 formalin (6% HgCl2, 12.5% CH3COONa, 4% formaldehyde), and sections stained (hematoxylin/eosin) or subjected to immunohistochemical analyses with antibodies specific for human B cells.
Southern blot assays. Tumor cell DNA was analyzed by Southern blots as described ( 13), using specific 32P-labeled DNA probes. 20 ,Ag of tumor cell genomic DNA was digested with Eco RI or Msp I, electrophoresed in 0.7% or 1.7% agarose gels, respectively, and transferred by the alkaline blot method to nylon membranes, which were hybridized with the DNA probes. EBV DNA was detected with an Msp I fragment of the B95-8 Bam HI K region (coding for EBNA-1), from a pBR322-EBV recombinant library (14) . Probes for c-myc and bc1-2 oncogenes were from Oncor, Gaithersburg, MD.
Results
EBV infection ofSCID/hu chimeras. PBL from four EBV-seronegative donors (designated J. R., D. P., N. H., and T. C.) and tonsil cells from one donor of unknown EBV status (age 4 yr) were transferred intraperitoneally to SCID mice. The mice were injected 7-16 d later with a 40-fold concentrate of B95-8 supernatant (usually 150 ,ul i.p. and/or 150 ,g i.v.), except for the recipients of 4-yr-old tonsil cells, which received 1 ml of B95-8 supernatant (0.8 ml i.p., 0.2 ml i.v.). These experiments are summarized in Table I Transfer ofEB V-transformed LCL to SCID mice. Since the tumors described above were undoubtedly a direct result of EBV infection of B cells in vivo, it was considered important to determine whether LCL derived by in vitro infection and transformation with EBV could also produce tumors in SCID mice. LCL established from three individuals were used in transfer experiments, a synopsis of which is provided in Table  II . Two of the LCLs, designated J. R. and D. P., respectively, were autologous to PBL used for SCID/hu chimeras. Although intraperitoneal EBV injection of the J. R. or D. P. SCID/hu PBL chimeras resulted in solid tumor formation, as described above, intraperitoneal transfer of 5 X 106 J. R. or D. P. LCL to SCID mice induced ascites production 14-21 d later. Autopsies did not reveal any other gross pathology and there was no evidence of tumor formation. Only 1-2 ml of ascites fluid could be aspirated from the peritoneal cavity, but > 1 X 108 cells were consistently recovered. FACS analysis indicated that the majority (> 90%) of these cells were of human B lymphoid origin. A notable feature ofthe ascites cells was that expression of the adhesion molecules ICAM-1 and LFA-3 was markedly depressed relative to the parent LCL. Ascites cell cultures in vitro showed little evidence of the clumping that is characteristic of LCL; this was presumably a reflection of ICAM-1 and LFA-3 downregulation.
J. R. and D. P. LCL were newly established lines, and had been in culture for about 1 mo. In contrast, the third LCL (designated R. S.), transferred to SCID mice was a long term cell line, having been continuously passaged for almost a year since its inception. RS LCL (3 X 106) were transferred intraperitoneally to each of three mice. Remarkably, no disease was seen in these mice until day 70 posttransfer, whereupon the first mouse became ill and was sacrificed. Autopsy revealed tumor masses in the abdomen, liver, and thymus. Similar gross pathology was observed in the second and third mice (days 81-86). Flow cytometry confirmed that the tumor cells were human B lymphoid cells. Histopathologic analysis indicated that the tumors were large cell immunoblastic nonplasmacytoid lymphomas, with less differentiation than the tumors seen after EBV infection of SCID/hu chimeras (Fig. 1 B) .
Discussion
We describe a new model for EBV-induced aggressive fatal human lymphoproliferative disease in SCID mice reconsti- (19) .
In summary, we have developed a novel animal model for EBV-induced human lymphoproliferative disorders and lymphomas. The model most closely resembles the EBV-related lymphoproliferative disorders that represent a frequent complication in immunosuppressed individuals receiving organ transplants, but it may also be a model for certain other EBVassociated lymphomas in man. Since the roles of EBV, the target B cell, and T cell immunity can be independently and rapidly assessed in this model system, further studies will yield insights into the role of each in the development of human lymphoproliferative disorders.
